{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:44:14Z","timestamp":1790185454702,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>In this study, we investigated the relationship of cerebral tau deposition (<jats:sup>18<\/jats:sup>F-tau-AD-ML 104 PET\/CT) with glucose metabolism (<jats:sup>18<\/jats:sup>F-FDG PET\/CT) and cognitive function in patients with Alzheimer disease (AD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Seventy subjects (Mini Mental State Examination [MMSE] score &lt;18 = 37 [AD]; MMSE score, 18\u201324 = 16 [early AD]) and 17 controls were included in this study. All participants underwent detailed neurological and neuropsychological evaluation, followed by <jats:sup>18<\/jats:sup>F-tau-AD-ML 104 and <jats:sup>18<\/jats:sup>F-FDG PET\/CT imaging. Region-wise SUV<jats:sub>max<\/jats:sub> ratios at 50 to 60 minutes postinjection were calculated for <jats:sup>18<\/jats:sup>F-tau-AD-ML 104 and <jats:sup>18<\/jats:sup>F-FDG, using the cerebellar cortex as the reference region. Linear models were used to investigate the association of regional <jats:sup>18<\/jats:sup>F-tau-AD-ML 104 retention with <jats:sup>18<\/jats:sup>F-FDG uptake and cognition (MMSE scores).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n                                 <jats:sup>18<\/jats:sup>F-Tau-AD-ML 104 retention was observed in the parietal lobe, temporal lobe, hippocampus, parahippocampus, frontal lobe, anterior and posterior cingulate, and precuneus in advanced and early AD patient as compared with normal controls with regional hypometabolism in overlapping regions on <jats:sup>18<\/jats:sup>F-FDG PET. Significant negative association was found between <jats:sup>18<\/jats:sup>F-tau-AD-ML 104 regional retention and glucose metabolism in the parietal lobe, temporal lobe, hippocampus, parahippocampus, frontal lobe, anterior and posterior cingulate, and precuneus among patients with advanced and early AD. In advanced and early AD patients, a negative association was found between <jats:sup>18<\/jats:sup>F-tau-AD-ML 104 regional retention (precuneus) and cognition (MMSE score), whereas a positive association was observed between <jats:sup>18<\/jats:sup>F-FDG regional uptake (precuneus) and cognition (MMSE score).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Tau pathology overlapped with areas of hypometabolism on FDG PET in the brains of AD patients. Tau deposition was found to have negative association with cognitive scores in these patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002791","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T14:39:37Z","timestamp":1570199977000},"page":"e597-e601","source":"Crossref","is-referenced-by-count":25,"title":["In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition"],"prefix":"10.1097","volume":"44","author":[{"given":"Vivek","family":"Baghel","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Parida","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravikant","family":"Gupta","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Yadav","sequence":"additional","affiliation":[{"name":"Geriatrics, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kumar","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Dey","sequence":"additional","affiliation":[{"name":"Geriatrics, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishikant Avinash","family":"Damle","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Kumar","sequence":"additional","affiliation":[{"name":"Geriatrics, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/brain\/awm140","article-title":"No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease","volume":"130","year":"2007","journal-title":"Brain"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease","volume":"129","year":"2006","journal-title":"Brain"},{"issue":"Pt 9","key":"bib3-20230925","first-page":"2320","article-title":"No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease","volume":"130","year":"2007","journal-title":"Brain"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"e0158460","DOI":"10.1371\/journal.pone.0158460","article-title":"Dynamic PET measures of Tau accumulation in cognitively normal older adults and Alzheimer's disease patients measured using [18F] THK-5351","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","article-title":"Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 Pet in a multimodal paradigm","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.24711","article-title":"In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum","volume":"80","year":"2016","journal-title":"Ann Neurol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research framework: towards a biological definition of Alzheimers disease","volume":"14","year":"2018","journal-title":"Alzheimers Dement"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","year":"2010","journal-title":"Lancet Neurol"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","year":"2011","journal-title":"Alzheimers Dement"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2967\/jnumed.115.170027","article-title":"Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40478-015-0220-4","article-title":"Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue","volume":"3","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-017-0162-3","article-title":"Tau PET imaging: present and future directions","volume":"12","year":"2017","journal-title":"Molecular Neurodegeneration"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes","volume":"82","year":"1991","journal-title":"Acta Neuropathol"},{"key":"bib14-20230925","first-page":"748","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition","volume":"140","year":"2017","journal-title":"Brain"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/0891988706297086","article-title":"Early-onset Alzheimer's disease is associated with greater pathologic burden","volume":"20","year":"2007","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimers disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","year":"2006","journal-title":"Acta Neuropathol"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","article-title":"The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease","volume":"52","year":"1999","journal-title":"Neurology"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","year":"2016","journal-title":"Ann Neurol"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","year":"2013","journal-title":"Neuron"},{"issue":"Pt 5","key":"bib21-20230925","first-page":"1551","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","year":"2016","journal-title":"Brain"},{"key":"bib22-20230925","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2967\/jnumed.117.197426","article-title":"Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib23-20230925","first-page":"25","article-title":"Monoamine oxidase B inhibitor, selegiline reduces F-18 THK 5351 uptake in human brain","volume":"9","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2967\/jnumed.118.209650","article-title":"In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2967\/jnumed.118.208215","article-title":"Brain imaging of Alzheimers dementia patients and elderly controls woth F-18 \u2013MK-6240, a PET tracer targeting neurofibrillary tangles","volume":"60","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:05:46Z","timestamp":1695621946000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002791","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}